Prague Med. Rep. 2015, 116, 24-30
https://doi.org/10.14712/23362936.2015.42
Possible Association between Erectile Dysfunction and Osteoporosis in Men
References
1. 1991) The association between testosterone, sexual arousal, and selective attention for erotic stimuli in men. Horm. Behav. 25, 367–381.
< , G. M., Sherwin, B. B. (https://doi.org/10.1016/0018-506X(91)90008-6>
2. 2003) Male osteoporosis: epidemiology and pathophysiology. Curr. Osteoporos. Rep. 1, 71–77.
< , S. (https://doi.org/10.1007/s11914-003-0012-9>
3. 2010) Testosterone-induced modulation of nitric oxide-cGMP signaling pathway and androgenesis in the rat Leydig cells. Biol. Reprod. 83(3), 434–442.
< , S. A., Janjic, M. M., Stojkov, N. J., Kostic, T. S. (https://doi.org/10.1095/biolreprod.110.083626>
4. 2012) Effects of inducible nitric oxide synthase (iNOS) deficiency in mice on Sertoli cell proliferation and perinatal testis development. Int. J. Androl. 35(5), 741–751.
< , S. A., Lara, N. L., Avelar, G. F., Sharpe, R. M., França, L. R. (https://doi.org/10.1111/j.1365-2605.2012.01264.x>
5. 1999) The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 84, 50–56.
< , I. A., McKinlay, J. B., Krane, R. J. (https://doi.org/10.1046/j.1464-410x.1999.00142.x>
6. 2010) Erectile dysfunction and low testosterone: cause or an effect? Can. J. Urol. 17, 2–11 (Suppl. 1).
, J. (
7. 2007) Sexual dysfunction in men and women with endocrine disorders. Lancet 369, 597–611.
< , S., Enzlin, P., Coviello, A., Basson, R. (https://doi.org/10.1016/S0140-6736(07)60280-3>
8. 1995) Bidirectional regulation of osteoclast function by nitric oxide synthase isoforms. Proc. Natl. Acad. Sci. U. S. A. 92, 2954–2958.
< , M. L., Hukkanen, M., Umeda, T., Moradi-Bidhendi, N., Bianchi, S., Gross, S. S., Polak, J. M., MacIntyre, I. (https://doi.org/10.1073/pnas.92.7.2954>
<PubMed>
9. 1995) Role of nitric oxide in the physiology of erection. Biol. Reprod. 52, 485–489.
< , A. L. (https://doi.org/10.1095/biolreprod52.3.485>
10. 1992) Nitric oxide: a physiologic mediator of penile erection. Science 257, 401–403.
< , A. L., Lowenstein, C. J., Bredt, D. S., Chang, T. S., Snyder, S. H. (https://doi.org/10.1126/science.1378650>
11. 2011) Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies. J. Am. Coll. Cardiol. 58, 1378–1385.
< , J. Y., Zhang, Y. H., Qin, L. Q. (https://doi.org/10.1016/j.jacc.2011.06.024>
12. 1999) Nitric oxide regulation of cGMP production in osteoclasts. J. Cell. Biochem. 73, 478–487.
< , S. S., Williams, J. P., Jordan, S. E., Cornwell, T., Blair, H. C. (https://doi.org/10.1002/(SICI)1097-4644(19990615)73:4<478::AID-JCB6>3.0.CO;2-T>
13. 2004) Osteopenia and male hypogonadism. Rev. Urol. 6, S30–S34 (Suppl. 6).
, K., Dobs, A. (
14. 2011) Sex and gender considerations in male patients with osteoporosis. Clin. Orthop. Relat. Res. 469, 1906–1912.
< , C. J., Lamont, L. E., Ton, Q. V., Lane, J. M. (https://doi.org/10.1007/s11999-011-1849-3>
<PubMed>
15. 2009) Erectile dysfunction (ED) is a shared sexual concern of couples I: couple conceptions of ED. J. Sex. Med. 6, 2746–2760.
< , W. A., Eardley, I., McCabe, M., Sand, M. (https://doi.org/10.1111/j.1743-6109.2009.01457.x>
16. 1986) Osteoporosis in hypogonadal men: role of decreased plasma 1,25dihydroxyvitamin D, calcium malabsorption, and low bone formation. Bone 7, 261–268.
< , R. M., Peacock, M., Aaron, J. E., Selby, P. L., Taylor, G. A., Thompson, J., Marshall, D. H., Horsman, A. (https://doi.org/10.1016/8756-3282(86)90205-X>
17. 1999) Nitric oxide and the cyclic GMP system in the penis. Mol. Urol. 3, 51–59.
, N. F., Ignarro, L. J., Rajfer, J. (
18. 1995) Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 91, 1314–1319.
< , R., Haefeli, W. E., Linder, L., Richard, V., Bakkali, E. H., Thuillez, C., Lüscher, T. F. (https://doi.org/10.1161/01.CIR.91.5.1314>
19. 2000) Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts male aging study. J. Urol. 163, 460–463.
< , C. B., Araujo, A. B., Feldman, H. A., Derby, C. A., Kleinman, K. P., McKinlay, J. B. (https://doi.org/10.1016/S0022-5347(05)67900-1>
20. 1994) Potentiation of osteoclast bone-resorption activity by inhibition of nitric oxide synthase. Proc. Natl. Acad. Sci. U. S. A. 91, 3569–3573.
< , T. P., Collin-Osdoby, P., Patel, N., Osdoby, P., Krukowski, M., Misko, T. P., Settle, S. L., Currie, M. G., Nickols, G. A. (https://doi.org/10.1073/pnas.91.9.3569>
<PubMed>
21. 1990) Reaction of the circulatory system to injury and regeneration. Clin. Orthop. Relat. Res. 254, 275–288.
, P. J., Montgomery, R. J., Bronk, J. T. (
22. 2008) Serum 25-hydroxyvitamin D and hip fracture risk in older U.S. white adults. J. Bone Miner. Res. 23, 143–150.
< , A. C., Mussolino, M. E. (https://doi.org/10.1359/jbmr.071003>
23. 1991) Osteoclastic inhibition: an action of nitric oxide not mediated by cyclic GMP. Proc. Natl. Acad. Sci. U. S. A. 88, 2936–2940.
< , I., Zaidi, M., Alam, A. S., Datta, H. K., Moonga, B. S., Lidbury, P. S., Hecker, M., Vane, J. R. (https://doi.org/10.1073/pnas.88.7.2936>
<PubMed>
24. 2010) Testosterone suppresses oxidative stress in human neutrophils. Cell Biochem. Funct. 28(5), 394–402.
< , D. P., Bolin, A. P., dos Santos Rde, C., Curi, R., Otton, R. (https://doi.org/10.1002/cbf.1669>
25. 2010) Summary of the recommendations on sexual dysfunctions in men. J. Sex. Med. 7, 3572–3588.
< , F., Adaikan, G., Becher, E., Giuliano, F., Khoury, S., Lue, T. F., Sharlip, I., Althof, S. E., Andersson, K. E., Brock, G., Broderick, G., Burnett, A., Buvat, J., Dean, J., Donatucci, C., Eardley, I., Fugl-Meyer, K. S., Goldstein, I., Hackett, G., Hatzichristou, D., Hellstrom, W., Incrocci, L., Jackson, G., Kadioglu, A., Levine, L., Lewis, R. W., Maggi, M., McCabe, M., McMahon, C. G., Montague, D., Motorsi, P., Mulhall, J., Pfaus, J., Porst, H., Ralph, D., Rosen, R., Rowland, D., Sadeghi-Nejad, H., Shabsigh, R., Stief, C., Vardi, Y., Wallen, K., Wasserman, M. (https://doi.org/10.1111/j.1743-6109.2010.02062.x>
26. 2003) Hypogonadism and erectile dysfunction: pathophysiological observations and therapeutic outcomes. BJU Int. 92, 896–899.
< , A., Heaton, J. P. W. (https://doi.org/10.1111/j.1464-410X.2003.04532.x>
27. 1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327, 524–526.
< , R. M., Ferrige, A. G., Moncada, S. (https://doi.org/10.1038/327524a0>
28. 2009) Risk factors for low BMD in healthy men age 50 years or older: a systematic review. Osteoporos. Int. 20, 507–518.
< , A., Kennedy, C. C., Cranney, A., Hawker, G., Brown, J. P., Kaiser, S. M., Leslie, W. D., O’Brien, C. J., Sawka, A. M., Khan, A., Siminoski, K., Tarulli, G., Webster, D., McGowan, J., Adachi, J. D. (https://doi.org/10.1007/s00198-008-0720-1>
<PubMed>
29. 1992) Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N. Engl. J. Med. 326, 90–94.
< , J., Aronson, W. J., Bush, P. A., Dorey, F. J., Ignarro, L. J. (https://doi.org/10.1056/NEJM199201093260203>
30. 1995) Nitric oxide: a cytokine-induced regulator of bone resorption. J. Bone Miner. Res. 10, 1040–1049.
< , S. H., Ho, L. P., Helfrich, M. H., Grabowski, P. S., Johnston, P. W., Benjamin, N. (https://doi.org/10.1002/jbmr.5650100708>
31. Robert-Koch-Institut (2011) Beiträge zur Gesundheitsberichterstattung des Bundes. Daten und Fakten: Ergebnisse der Studie “Gesundheit in Deutschland aktuell”. Available at: http://www.gbe-bund.de
32. 2004) The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J. Urol. 171, 2341–2345.
< , A. D., Sun, P., Swindle, R. (https://doi.org/10.1097/01.ju.0000125198.32936.38>
33. 2010) Hypogonadism, erectile dysfunction, and type 2 diabetes mellitus: what the clinician needs to know. Postgrad. Med. 122, 165–175.
< , R., Deveney, T. (https://doi.org/10.3810/pgm.2010.11.2234>
34. 2007) Rationale for using nitric oxide donor therapy for prevention of bone loss and treatment of osteoporosis in humans. Ann. N. Y. Acad. Sci. 1117, 283–297.
< , S. J. (https://doi.org/10.1196/annals.1402.066>